A two-year partnership with Ultrahuman aims to connect clinical biomarkers and wearable data, bringing aging assessment into ...

GPX4-targeting therapy reduces epigenetic age markers and circulating inflammation, raising questions about effects beyond ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

At LIC 2026, investors, scientists and founders examined what survives the journey from longevity hypothesis to human ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...